The DOI matches its Crossref record; 628 of the 628 references it cites were found in a registry or an index.
Targeting cytokine and chemokine signaling pathways for cancer therapy
Open accessAbstract
Cytokines are critical in regulating immune responses and cellular behavior, playing dual roles in both normal physiology and the pathology of diseases such as cancer. These molecules, including interleukins, interferons, tumor necrosis factors, chemokines, and growth factors like TGF-β, VEGF, and EGF, can promote or inhibit tumor growth, influence the tumor microenvironment, and impact the efficacy of cancer treatments. Recent advances in targeting these pathways have shown promising therapeutic potential, offering new strategies to modulate the immune system, inhibit tumor progression, and overcome resistance to conventional therapies. In this review, we summarized the current understanding and therapeutic implications of targeting cytokine and chemokine signaling pathways in cancer. By exploring the roles of these molecules in tumor biology and the immune response, we highlighted the development of novel therapeutic agents aimed at modulating these pathways to combat cancer. The review elaborated on the dual nature of cytokines as both promoters and suppressors of tumorigenesis, depending on the context, and discussed the challenges and opportunities this presents for therapeutic intervention. We also examined the latest advancements in targeted therapies, including monoclonal antibodies, bispecific antibodies, receptor inhibitors, fusion proteins, engineered cytokine variants, and their impact on tumor growth, metastasis, and the tumor microenvironment. Additionally, we evaluated the potential of combining these targeted therapies with other treatment modalities to overcome resistance and improve patient outcomes. Besides, we also focused on the ongoing research and clinical trials that are pivotal in advancing our understanding and application of cytokine- and chemokine-targeted therapies for cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–400 of 628
Wu, Y.-L., Yang, J. C.-H., Kim, D.-W., Lu, S., Zhou, J., Seto, T., Yang, J.-J., Yamamoto, N., Ahn, M.-J., Takahashi, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.5587 · Cited by 326
Self-citationRecent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
Qin, S., Li, A., Yi, M., Yu, S., Zhang, M., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0718-5 · Cited by 324
Self-citationOsimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
Remon, J., Steuer, C. E., Ramalingam, S. S., & Felip, E. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx704 · Cited by 322
Knall, C., Worthen, G. S., & Johnson, G. L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.3052 · Cited by 321
Sangro, B., Mazzolini, G., Ruiz, J., Herraiz, M., Quiroga, J., Herrero, I., Benito, A., Larrache, J., Pueyo, J., Subtil, J. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.059 · Cited by 320
Motzer, R. J., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Shah, A. Y., Suárez, C., Hamzaj, A., Porta, C., Hocking, C. M., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00290-x · Cited by 318
CCL2/CCR2 signaling in cancer pathogenesis
Hao, Q., Vadgama, J. V., & Wang, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00589-8 · Cited by 315
Type I interferon-mediated tumor immunity and its role in immunotherapy
Yu, R., Zhu, B., & Chen, D. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04219-z · Cited by 309
Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell Carcinoma
Gleave, M. E., Elhilali, M., Fradet, Y., Davis, I., Venner, P., Saad, F., Klotz, L. H., Moore, M. J., Paton, V., Bajamonde, A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804303381804 · Cited by 308
Mortier, E., Quéméner, A., Vusio, P., Lorenzen, I., Boublik, Y., Grötzinger, J., Plet, A., & Jacques, Y. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508624200 · Cited by 308
Sade-Feldman, M., Kanterman, J., Ish-Shalom, E., Elnekave, M., Horwitz, E., & Baniyash, M. (2013) · Immunity · doi:10.1016/j.immuni.2013.02.007 · Cited by 307
Chua, A. O., Chizzonite, R., Desai, B. B., Truitt, T. P., Nunes, P., Minetti, L. J., Warrier, R. R., Presky, D. H., Levine, J. F., Gately, M. K., et al. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.1.128 · Cited by 306
Current and future status of JAK inhibitors
McLornan, D. P., Pope, J. E., Gotlib, J., & Harrison, C. N. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00438-4 · Cited by 305
Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
Hunter, F. W., Barker, H. R., Lipert, B., Rothé, F., Gebhart, G., Piccart-Gebhart, M. J., Sotiriou, C., & Jamieson, S. M. F. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0635-y · Cited by 304
Role of HER2 gene overexpression in breast carcinoma
M�nard, S., Tagliabue, E., Campiglio, M., & Pupa, S. M. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200002)182:2<150::aid-jcp3>3.0.co;2-e · Cited by 303
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
Wang, S., Cang, S., & Liu, D. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0268-z · Cited by 302
Targeting IL-10 Family Cytokines for the Treatment of Human Diseases
Wang, X., Wong, K., Ouyang, W., & Rutz, S. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028548 · Cited by 302
Tofacitinib: A Review in Rheumatoid Arthritis
Dhillon, S. (2017) · Drugs · doi:10.1007/s40265-017-0835-9 · Cited by 302
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin
Pang, N., Shi, J., Qin, L., Chen, A., Tang, Y., Yang, H., Huang, Y., Wu, Q., Li, X., He, B., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01128-9 · Cited by 301
Self-citationOpposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients
Parmiani, G., Castelli, C., Pilla, L., Santinami, M., Colombo, M. P., & Rivoltini, L. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl158 · Cited by 300
Melisi, D., Garcia-Carbonero, R., Macarulla, T., Pezet, D., Deplanque, G., Fuchs, M., Trojan, J., Oettle, H., Kozloff, M., Cleverly, A., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0246-z · Cited by 294
EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance
Wang, S., Song, Y., & Liu, D. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.11.008 · Cited by 293
Convergence between Wnt-β-catenin and EGFR signaling in cancer
Hu, T., & Li, C. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-236 · Cited by 291
The role of interleukin 1 in growth and metastasis of human cancer xenografts.
Elaraj, D. M., Weinreich, D. M., Varghese, S., Puhlmann, M., Hewitt, S. M., Carroll, N. M., Feldman, E. D., Turner, E. M., & Alexander, H. R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1603 · Cited by 288
IL-12 receptor. II. Distribution and regulation of receptor expression
Desai, B. B., Quinn, P. M., Wolitzky, A. G., Mongini, P. K., Chizzonite, R., & Gately, M. K. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.10.3125 · Cited by 287
Eggermont, A. M. M., Suciu, S., Testori, A., Santinami, M., Kruit, W. H. J., Marsden, J., Punt, C. J. A., Salès, F., Dummer, R., Robert, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.3799 · Cited by 285
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis
Heczey, A., Courtney, A. N., Montalbano, A., Robinson, S., Liu, K., Li, M., Ghatwai, N., Dakhova, O., Liu, B., Raveh-Sadka, T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1074-2 · Cited by 285
CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells
Velasco-Velázquez, M., Jiao, X., De La Fuente, M., Pestell, T. G., Ertel, A., Lisanti, M. P., & Pestell, R. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3917 · Cited by 282
Greene, S., Robbins, Y., Mydlarz, W. K., Huynh, A. P., Schmitt, N. C., Friedman, J., Horn, L. A., Palena, C., Schlom, J., Maeda, D. Y., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2625 · Cited by 280
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells
Codarri Deak, L., Nicolini, V., Hashimoto, M., Karagianni, M., Schwalie, P. C., Lauener, L., Varypataki, E. M., Richard, M., Bommer, E., Sam, J., et al. (2022) · Nature · doi:10.1038/s41586-022-05192-0 · Cited by 280
Giaccone, G., Bazhenova, L. A., Nemunaitis, J., Tan, M., Juhász, E., Ramlau, R., van den Heuvel, M. M., Lal, R., Kloecker, G. H., Eaton, K. D., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.07.035 · Cited by 279
Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
Zhou, W., Guo, S., Liu, M., Burow, M. E., & Wang, G. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666170830111531 · Cited by 278
Yasuda, S., Sho, M., Yamato, I., Yoshiji, H., Wakatsuki, K., Nishiwada, S., Yagita, H., & Nakajima, Y. (2013) · Clinical and Experimental Immunology · doi:10.1111/cei.12069 · Cited by 276
Bilusic, M., Heery, C. R., Collins, J. M., Donahue, R. N., Palena, C., Madan, R. A., Karzai, F., Marté, J. L., Strauss, J., Gatti-Mays, M. E., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0706-x · Cited by 274
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
Brand, T. M., Iida, M., & Wheeler, D. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.9.15050 · Cited by 273
Brandes, A. A., Carpentier, A. F., Kesari, S., Sepulveda-Sanchez, J. M., Wheeler, H. R., Chinot, O., Cher, L., Steinbach, J. P., Capper, D., Specenier, P., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now009 · Cited by 273
Sandhu, S. K., Papadopoulos, K., Fong, P. C., Patnaik, A., Messiou, C., Olmos, D., Wang, G., Tromp, B. J., Puchalski, T. A., Balkwill, F., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2099-8 · Cited by 272
Sacco, A. G., Chen, R., Worden, F. P., Wong, D. J. L., Adkins, D., Swiecicki, P., Chai-Ho, W., Oppelt, P., Ghosh, D., Bykowski, J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00136-4 · Cited by 271
Emmerich, J., Mumm, J. B., Chan, I. H., LaFace, D., Truong, H., McClanahan, T., Gorman, D. M., & Oft, M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0721 · Cited by 270
Solal-Celigny, P., Lepage, E., Brousse, N., Reyes, F., Haioun, C., Leporrier, M., Peuchmaur, M., Bosly, A., Parlier, Y., Brice, P., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311253292203 · Cited by 268
Differential regulation of interleukin 1 receptor and Toll-like receptor signaling by MEKK3
Huang, Q., Yang, J., Lin, Y., Walker, C., Cheng, J., Liu, Z.-G., & Su, B. (2004) · Nature Immunology · doi:10.1038/ni1014 · Cited by 266
GM-CSF: A Double-Edged Sword in Cancer Immunotherapy
Kumar, A., Taghi Khani, A., Sanchez Ortiz, A., & Swaminathan, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.901277 · Cited by 265
TGF-β signaling in the tumor metabolic microenvironment and targeted therapies
Shi, X., Yang, J., Deng, S., Xu, H., Wu, D., Zeng, Q., Wang, S., Hu, T., Wu, F., & Zhou, H. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01349-6 · Cited by 262
CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis
Zhang, J., Patel, L., & Pienta, K. J. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.009 · Cited by 261
Interferon-ε Protects the Female Reproductive Tract from Viral and Bacterial Infection
Fung, K. Y., Mangan, N. E., Cumming, H., Horvat, J. C., Mayall, J. R., Stifter, S. A., De Weerd, N., Roisman, L. C., Rossjohn, J., Robertson, S. A., et al. (2013) · Science · doi:10.1126/science.1233321 · Cited by 261
Song, Y., Fu, Y., Xie, Q., Zhu, B., Wang, J., & Zhang, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01956 · Cited by 261
Choueiri, T. K., Larkin, J., Oya, M., Thistlethwaite, F., Martignoni, M., Nathan, P., Powles, T., McDermott, D., Robbins, P. B., Chism, D. D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30107-4 · Cited by 260 · cited 1×
“534,535 Additionally, Xu et al. reported a phase I study (NCT02942329) combining SHR-1210 (anti-PD-1 antibody) with apatinib in various cancers, noting particularly favorable results in hepatocellular carcinoma patients.”
BackgroundImmunomodulatory TGF-β Signaling in Hepatocellular Carcinoma
Chen, J., Gingold, J. A., & Su, X. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.06.007 · Cited by 260
A chemokine receptor antagonist inhibits experimental breast tumor growth.
Robinson, S. C., Scott, K. A., Wilson, J. L., Thompson, R. G., Proudfoot, A. E. I., & Balkwill, F. R. (2003) · PubMed · Cited by 259
Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer
Formenti, S. C., Lee, P., Adams, S., Goldberg, J. D., Li, X., Xie, M. W., Ratikan, J. A., Felix, C., Hwang, L., Faull, K. F., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3322 · Cited by 257
Nakamura, T., Sato, T., Endo, R., Sasaki, S., Takahashi, N., Sato, Y., Hyodo, M., Hayakawa, Y., & Harashima, H. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002852 · Cited by 257
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
Wang, Y., Zhang, H., Liu, C., Wang, Z., Wu, W., Zhang, N., Zhang, L., Hu, J., Luo, P., Zhang, J., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01325-0 · Cited by 257
Self-citationSustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
Jacquelot, N., Yamazaki, T., Roberti, M. P., Duong, C. P. M., Andrews, M. C., Verlingue, L., Ferrere, G., Becharef, S., Vétizou, M., Daillère, R., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0224-x · Cited by 256
Brose, M. S., Robinson, B., Sherman, S. I., Krajewska, J., Lin, C.-C., Vaisman, F., Hoff, A. O., Hitre, E., Bowles, D. W., Hernando, J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00332-6 · Cited by 256
Meric-Bernstam, F., Sweis, R. F., Kasper, S., Hamid, O., Bhatia, S., Dummer, R., Stradella, A., Long, G. V., Spreafico, A., Shimizu, T., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2235 · Cited by 248
IL-15 in the Combination Immunotherapy of Cancer
Waldmann, T. A., Dubois, S., Miljkovic, M. D., & Conlon, K. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00868 · Cited by 247
Righi, E., Kashiwagi, S., Yuan, J., Santosuosso, M., Leblanc, P., Ingraham, R., Forbes, B., Edelblute, B., Collette, B., Xing, D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3143 · Cited by 245
Salem, J.-E., Bretagne, M., Abbar, B., Leonard-Louis, S., Ederhy, S., Redheuil, A., Boussouar, S., Nguyen, L. S., Procureur, A., Stein, F., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1180 · Cited by 243
Hoellenriegel, J., Zboralski, D., Maasch, C., Rosin, N. Y., Wierda, W. G., Keating, M. J., Kruschinski, A., & Burger, J. A. (2014) · Blood · doi:10.1182/blood-2013-03-493924 · Cited by 242
Knall, C., Young, S., Nick, J. A., Buhl, A. M., Worthen, G. S., & Johnson, G. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.5.2832 · Cited by 242
Moschos, S. J., Edington, H. D., Land, S. R., Rao, U. N., Jukic, D., Shipe-Spotloe, J., & Kirkwood, J. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2498 · Cited by 242
Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial
Windbichler, G. H., Hausmaninger, H., Stummvoll, W., Graf, A. H., Kainz, C., Lahodny, J., Denison, U., Müller-Holzner, E., & Marth, C. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1053 · Cited by 241
Kurose, K., Ohue, Y., Wada, H., Iida, S., Ishida, T., Kojima, T., Doi, T., Suzuki, S., Isobe, M., Funakoshi, T., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0357 · Cited by 241
The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies
Daniel, S. K., Seo, Y. D., & Pillarisetty, V. G. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.007 · Cited by 239
Lo, H.-W., Hsu, S.-C., & Hung, M.-C. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9011-0 · Cited by 237
Diab, A., Tannir, N. M., Bentebibel, S.-E., Hwu, P., Papadimitrakopoulou, V., Haymaker, C., Kluger, H. M., Gettinger, S. N., Sznol, M., Tykodi, S. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1510 · Cited by 237
HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence
Fu, J., Su, X., Li, Z., Deng, L., Liu, X., Feng, X., & Peng, J. (2021) · Oncogene · doi:10.1038/s41388-021-01863-w · Cited by 235
Yi, M., Zhang, J., Li, A., Niu, M., Yan, Y., Jiao, Y., Luo, S., Zhou, P., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01045-x · Cited by 233
Self-citationDong, J., Cheng, X.-D., Zhang, W.-D., & Qin, J.-J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00629 · Cited by 232
Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review
Zou, X., Tang, X.-Y., Qu, Z.-Y., Sun, Z.-W., Ji, C.-F., Li, Y.-J., & Guo, S.-D. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.01.113 · Cited by 232
Wang, S., Campos, J., Gallotta, M., Gong, M., Crain, C., Naik, E., Coffman, R. L., & Guiducci, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608555113 · Cited by 231
(2019) · doi:10.1158/2159-8290.cd-18-1495 · Cited by 231
The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance
Huang, X., Gan, G., Wang, X., Xu, T., & Xie, W. (2019) · Autophagy · doi:10.1080/15548627.2019.1580105 · Cited by 230
DEMONSTRATION AND CHARACTERIZATION OF TWO DISTINCT HUMAN LEUKOCYTIC PYROGENS
Dinarello, C. A., Goldin, N. P., & Wolff, S. M. (1974) · The Journal of Experimental Medicine · doi:10.1084/jem.139.6.1369 · Cited by 229
Type I Interferons Protect T Cells against NK Cell Attack Mediated by the Activating Receptor NCR1
Crouse, J., Bedenikovic, G., Wiesel, M., Ibberson, M., Xenarios, I., Von Laer, D., Kalinke, U., Vivier, E., Jonjic, S., & Oxenius, A. (2014) · Immunity · doi:10.1016/j.immuni.2014.05.003 · Cited by 229
The role IL-1 in tumor-mediated angiogenesis
Voronov, E., Carmi, Y., & Apte, R. N. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00114 · Cited by 228
Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma.
Caruso, M., Pham-Nguyen, K., Kwong, Y. L., Xu, B., Kosai, K. I., Finegold, M., Woo, S. L., & Chen, S. H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11302 · Cited by 227
Van Overmeire, E., Stijlemans, B., Heymann, F., Keirsse, J., Morias, Y., Elkrim, Y., Brys, L., Abels, C., Lahmar, Q., Ergen, C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0869 · Cited by 227
Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment
Hewitt, S. L., Bailey, D., Zielinski, J., Apte, A., Musenge, F., Karp, R., Burke, S., Garcon, F., Mishra, A., Gurumurthy, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0472 · Cited by 227
The Role of IL-6 in Cancer Cell Invasiveness and Metastasis—Overview and Therapeutic Opportunities
Rašková, M., Lacina, L., Kejík, Z., Venhauerová, A., Skaličková, M., Kolář, M., Jakubek, M., Rosel, D., Smetana, K., & Brábek, J. (2022) · Cells · doi:10.3390/cells11223698 · Cited by 226
Exploiting innate immunity for cancer immunotherapy
Yi, M., Li, T., Niu, M., Mei, Q., Zhao, B., Chu, Q., Dai, Z., & Wu, K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01885-w · Cited by 225
Self-citationHan, K.-P., Zhu, X., Liu, B., Jeng, E., Kong, L., Yovandich, J. L., Vyas, V. V., Marcus, W. D., Chavaillaz, P.-A., Romero, C. A., et al. (2011) · Cytokine · doi:10.1016/j.cyto.2011.09.028 · Cited by 223
Trastuzumab in the Treatment of Breast Cancer
Maximiano, S., Magalhães, P., Guerreiro, M. P., & Morgado, M. (2016) · BioDrugs · doi:10.1007/s40259-016-0162-9 · Cited by 223
Naing, A., Papadopoulos, K. P., Autio, K. A., Ott, P. A., Patel, M. R., Wong, D. J., Falchook, G. S., Pant, S., Whiteside, M., Rasco, D. R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.1106 · Cited by 222
Liu, J. F., Herold, C., Gray, K. P., Penson, R. T., Horowitz, N., Konstantinopoulos, P. A., Castro, C. M., Hill, S. J., Curtis, J., Luo, W., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3343 · Cited by 222
Targeting MET Dysregulation in Cancer
Recondo, G., Che, J., Jänne, P. A., & Awad, M. M. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1446 · Cited by 221
Higgs, B. W., Morehouse, C. A., Streicher, K., Brohawn, P. Z., Pilataxi, F., Gupta, A., & Ranade, K. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3451 · Cited by 220
Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?
Fei, L., Ren, X., Yu, H., & Zhan, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.771210 · Cited by 219
Lu, S., Wu, L., Jian, H., Cheng, Y., Wang, Q., Fang, J., Wang, Z., Hu, Y., Han, L., Sun, M., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00135-2 · Cited by 214
Pant, S., Schuler, M., Iyer, G., Witt, O., Doi, T., Qin, S., Tabernero, J., Reardon, D. A., Massard, C., Minchom, A., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00275-9 · Cited by 213
Xie, M., Lin, Z., Ji, X., Luo, X., Zhang, Z., Sun, M., Chen, X., Zhang, B., Liang, H., Liu, D., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.036 · Cited by 212
Maraviroc: a review of its use in HIV infection and beyond
Kanmogne, G., & Woollard, S. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s90580 · Cited by 211
Hu, B., Yu, M., Ma, X., Sun, J., Liu, C., Wang, C., Wu, S., Fu, P., Yang, Z., He, Y., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1022 · Cited by 211
Cho, H., Seo, Y., Loke, K. M., Kim, S.-W., Oh, S.-M., Kim, J.-H., Soh, J., Kim, H. S., Lee, H., Kim, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0125 · Cited by 210
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors
Margolin, K., Morishima, C., Velcheti, V., Miller, J. S., Lee, S. M., Silk, A. W., Holtan, S. G., Lacroix, A. M., Fling, S. P., Kaiser, J. C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0945 · Cited by 208
Tumour necrosis factor and cancer
Waters, J. P., Pober, J. S., & Bradley, J. R. (2013) · The Journal of Pathology · doi:10.1002/path.4188 · Cited by 206
Dubois, S., Patel, H. J., Zhang, M., Waldmann, T. A., & Müller, J. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2099 · Cited by 205
Paz-Ares, L., Kim, T. M., Vicente, D., Felip, E., Lee, D. H., Lee, K. H., Lin, C.-C., Flor, M. J., Di Nicola, M., Alvarez, R. M., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.003 · Cited by 205
Angevin, E., Tabernero, J., Elez, E., Cohen, S. J., Bahleda, R., van Laethem, J.-L., Ottensmeier, C., Lopez-Martin, J. A., Clive, S., Joly, F., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2200 · Cited by 203
Mody, R., Yu, A. L., Naranjo, A., Zhang, F. F., London, W. B., Shulkin, B. L., Parisi, M. T., Servaes, S.-E.-N., Diccianni, M. B., Hank, J. A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00203 · Cited by 202
TGF-β Signaling in Liver, Pancreas, and Gastrointestinal Diseases and Cancer
Gough, N. R., Xiang, X., & Mishra, L. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.064 · Cited by 202
Tumor-targeted delivery of a STING agonist improves cancer immunotherapy
Wu, Y.-T., Fang, Y., Wei, Q., Shi, H., Tan, H., Deng, Y., Zeng, Z., Qiu, J., Chen, C., Sun, L., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2214278119 · Cited by 201
Self-citationHER2-targeted therapies in gastric cancer
Zhu, Y., Zhu, X., Wei, X., Tang, C., & Zhang, W. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188549 · Cited by 200
Viral Vector-Based Gene Therapy
Li, X., Le, Y., Zhang, Z., Nian, X., Liu, B., & Yang, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097736 · Cited by 200
SnapShot: EGFR Signaling Pathway
Yarden, Y., & Shilo, B.-Z. (2007) · Cell · doi:10.1016/j.cell.2007.11.013 · Cited by 199
Hong, D. S., Hui, D., Bruera, E., Janku, F., Naing, A., Falchook, G. S., Piha-Paul, S., Wheler, J. J., Fu, S., Tsimberidou, A. M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70155-x · Cited by 199
Noel, M., O’Reilly, E. M., Wolpin, B. M., Ryan, D. P., Bullock, A. J., Britten, C. D., Linehan, D. C., Belt, B. A., Gamelin, E. C., Ganguly, B., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-019-00830-3 · Cited by 199
Dijkgraaf, E. M., Santegoets, S. J. A. M., Reyners, A. K. L., Goedemans, R., Wouters, M. C. A., Kenter, G. G., van Erkel, A. R., van Poelgeest, M. I. E., Nijman, H. W., van der Hoeven, J. J. M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv309 · Cited by 197
Fizazi, K., De Bono, J. S., Flechon, A., Heidenreich, A., Voog, E., Davis, N. B., Qi, M., Bandekar, R., Vermeulen, J. T., Cornfeld, M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.014 · Cited by 197
Miller, J. S., Morishima, C., McNeel, D. G., Patel, M. R., Kohrt, H. E. K., Thompson, J. A., Sondel, P. M., Wakelee, H. A., Disis, M. L., Kaiser, J. C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2451 · Cited by 197
Makkouk, A., Yang, X. (., Barca, T., Lucas, A., Turkoz, M., Wong, J. T. S., Nishimoto, K. P., Brodey, M. M., Tabrizizad, M., Gundurao, S. R. Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003441 · Cited by 197
The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
Cai, W.-Q., Zeng, L.-S., Wang, L.-F., Wang, Y.-Y., Cheng, J.-T., Zhang, Y., Han, Z.-W., Zhou, Y., Huang, S.-L., Wang, X.-W., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01249 · Cited by 196
Simonsson, B., Gedde-Dahl, T., Markevärn, B., Remes, K., Stentoft, J., Almqvist, A., Björeman, M., Flogegård, M., Koskenvesa, P., Lindblom, A., et al. (2011) · Blood · doi:10.1182/blood-2011-02-336685 · Cited by 194
Tumor angiogenesis revisited: Regulators and clinical implications
Ronca, R., Benkheil, M., Mitola, S., Struyf, S., & Liekens, S. (2017) · Medicinal Research Reviews · doi:10.1002/med.21452 · Cited by 193
CXCR4 Inhibition with AMD3100 Sensitizes Prostate Cancer to Docetaxel Chemotherapy
Domanska, U. M., Timmer-Bosscha, H., Nagengast, W. B., Oude Munnink, T. H., Kruizinga, R. C., Ananias, H. J. K., Kliphuis, N. M., Huls, G., De Vries, E. G. E., de Jong, I. J., et al. (2012) · Neoplasia · doi:10.1593/neo.12324 · Cited by 191
New perspectives in cancer immunotherapy: targeting IL-6 cytokine family
Soler, M. F., Abaurrea, A., Azcoaga, P., Araujo, A. M., & Caffarel, M. M. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007530 · Cited by 191
Twist1 Induces CCL2 and Recruits Macrophages to Promote Angiogenesis
Low-Marchelli, J. M., Ardi, V. C., Vizcarra, E. A., van Rooijen, N., Quigley, J. P., & Yang, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-0653 · Cited by 190
Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC
Kargl, J., Zhu, X., Zhang, H., Yang, G. H. Y., Friesen, T. J., Shipley, M., Maeda, D. Y., Zebala, J. A., McKay-Fleisch, J., Meredith, G., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130850 · Cited by 190
Self-citationMoskowitz, A. J., Ghione, P., Jacobsen, E., Ruan, J., Schatz, J. H., Noor, S., Myskowski, P., Vardhana, S., Ganesan, N., Hancock, H., et al. (2021) · Blood · doi:10.1182/blood.2021013379 · Cited by 190
Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy
Zhu, X., Fujita, M., Snyder, L. A., & Okada, H. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0473-5 · Cited by 189
Hendry, S. A., Farnsworth, R. H., Solomon, B., Achen, M. G., Stacker, S. A., & Fox, S. B. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00621 · Cited by 188
Choi, Y., & Jung, K. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01114-w · Cited by 188
CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy
Huseni, M. A., Wang, L., Klementowicz, J. E., Yuen, K., Breart, B., Orr, C., Liu, L.-F., Li, Y., Gupta, V., Li, C., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100878 · Cited by 188
Vimalraj, S. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.09.129 · Cited by 186
Swain, S. M., Nishino, M., Lancaster, L. H., Li, B. T., Nicholson, A. G., Bartholmai, B. J., Naidoo, J., Schumacher-Wulf, E., Shitara, K., Tsurutani, J., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102378 · Cited by 185
TNF in the era of immune checkpoint inhibitors: friend or foe?
Chen, A. Y., Wolchok, J. D., & Bass, A. R. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00584-4 · Cited by 183
STING agonist promotes CAR T cell trafficking and persistence in breast cancer
Xu, N., Palmer, D. C., Robeson, A. C., Shou, P., Bommiasamy, H., Laurie, S. J., Willis, C., Dotti, G., Vincent, B. G., Restifo, N. P., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20200844 · Cited by 181
Glassman, C. R., Mathiharan, Y. K., Jude, K. M., Su, L., Panova, O., Lupardus, P. J., Spangler, J. B., Ely, L. K., Thomas, C., Skiniotis, G., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.018 · Cited by 181
Anakinra for rheumatoid arthritis
Mertens, M., & Singh, J. A. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005121.pub3 · Cited by 179
Antitumor Effects of Interferon Preparations In Mice
Gresser, I., & Bourali, C. (1970) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/45.2.365 · Cited by 179
How microorganisms tip the balance between interleukin-12 family members
Goriely, S., Neurath, M. F., & Goldman, M. (2008) · Nature Reviews Immunology · doi:10.1038/nri2225 · Cited by 179
Christodoulou, I., Ho, W. J., Marple, A., Ravich, J. W., Tam, A., Rahnama, R., Fearnow, A., Rietberg, C., Yanik, S., Solomou, E. E., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003894 · Cited by 179
Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy
Tu, M. M., Abdel-Hafiz, H. A., Jones, R. T., Jean, A., Hoff, K. J., Duex, J. E., Chauca-Diaz, A., Costello, J. C., Dancik, G. M., Tamburini, B. A. J., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01441-y · Cited by 178
Lesch, S., Blumenberg, V., Stoiber, S., Gottschlich, A., Ogonek, J., Cadilha, B. L., Dantes, Z., Rataj, F., Dorman, K., Lutz, J., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00737-6 · Cited by 178
Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis
Qiao, J., Liu, Z., Dong, C., Luan, Y., Zhang, A., Moore, C., Fu, K., Peng, J., Wang, Y., Ren, Z., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.005 · Cited by 176
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01363-8 · Cited by 175
Self-citationBurchert, A., Müller, M. C., Kostrewa, P., Erben, P., Bostel, T., Liebler, S., Hehlmann, R., Neubauer, A., & Hochhaus, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.5075 · Cited by 174
Lu, X., Yu, L., Zhang, Z., Ren, X., Smaill, J. B., & Ding, K. (2018) · Medicinal Research Reviews · doi:10.1002/med.21488 · Cited by 173
Luke, J. J., Piha-Paul, S. A., Medina, T., Verschraegen, C. F., Varterasian, M., Brennan, A. M., Riese, R. J., Sokolovska, A., Strauss, J., Hava, D. L., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0118 · Cited by 173
Zhang, M., Huang, L., Ding, G., Huang, H., Cao, G., Sun, X., Lou, N., Wei, Q., Shen, T., Xu, X., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000308 · Cited by 172
Strauss, J., Heery, C. R., Kim, J. W., Jochems, C., Donahue, R. N., Montgomery, A. S., McMahon, S., Lamping, E., Marté, J. L., Madan, R. A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1512 · Cited by 171
Meder, L., Schuldt, P., Thelen, M., Schmitt, A., Dietlein, F., Klein, S., Borchmann, S., Wennhold, K., Vlasic, I., Oberbeck, S., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2176 · Cited by 170
Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling
Zhang, X.-N., Yang, K.-D., Chen, C., He, Z.-C., Wang, Q.-H., Feng, H., Lv, S.-Q., Wang, Y., Mao, M., Liu, Q., et al. (2021) · Cell Research · doi:10.1038/s41422-021-00528-3 · Cited by 170
Self-citationJiang, H., Gebhardt, C., Umansky, L., Beckhove, P., Schulze, T. J., Utikal, J., & Umansky, V. (2015) · International Journal of Cancer · doi:10.1002/ijc.29297 · Cited by 169
Tumors establish resistance to immunotherapy by regulating T reg recruitment via CCR4
Marshall, L. A., Marubayashi, S., Jorapur, A., Jacobson, S., Zibinsky, M., Robles, O., Hu, D. X., Jackson, J. J., Pookot, D., Sanchez, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000764 · Cited by 169
Thomas, S., Kuncheria, L., Roulstone, V., Kyula, J. N., Mansfield, D., Bommareddy, P. K., Smith, H., Kaufman, H. L., Harrington, K. J., & Coffin, R. S. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0682-1 · Cited by 168
Xu, Z., Guo, D., Jiang, Z., Tong, R., Jiang, P., Bai, L., Chen, L., Zhu, Y., Guo, C., Shi, J., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111682 · Cited by 168
Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
Du, X., Yang, B., An, Q., Assaraf, Y. G., Cao, X., & Xia, J. (2021) · The Innovation · doi:10.1016/j.xinn.2021.100103 · Cited by 168
Dysregulation in IFN-γ signaling and response: the barricade to tumor immunotherapy
Han, J., Wu, M., & Liu, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1190333 · Cited by 168
Grinberg-Bleyer, Y., Saadoun, D., Baeyens, A., Billiard, F., Goldstein, J. D., Grégoire, S., Martin, G. H., Elhage, R., Derian, N., Carpentier, W., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42945 · Cited by 167
Laskin, J., Liu, S. V., Tolba, K., Heining, C., Schlenk, R. F., Cheema, P., Cadranel, J., Jones, M. R., Drilon, A., Cseh, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2335 · Cited by 167
Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC
Keegan, A., Ricciuti, B., Garden, P. M., Cohen, L., Nishihara, R., Adeni, A. E., Paweletz, C. P., Supplee, J., Janne, P. A., Severgnini, M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000678 · Cited by 167
Yi, M., Wu, Y., Niu, M., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Dai, Z., & Wu, K. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005543 · Cited by 167
Self-citationPere, H., Montier, Y., Bayry, J., Quintin-Colonna, F., Merillon, N., Dransart, E., Badoual, C., Gey, A., Ravel, P., Marcheteau, E., et al. (2011) · Blood · doi:10.1182/blood-2011-01-329656 · Cited by 166
Kim, P. S., Kwilas, A. R., Xu, W. V., Alter, S., Jeng, E. K., Wong, H. C., Schlom, J., & Hodge, J. W. (2016) · Oncotarget · doi:10.18632/oncotarget.7470 · Cited by 166
Zheng, X., Wu, Y., Bi, J., Huang, Y., Cheng, Y., Li, Y., Wu, Y., Cao, G., & Tian, Z. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00786-6 · Cited by 166
Self-citationWu, T.-C., Xu, K., Martinek, J., Young, R. R., Banchereau, R., George, J., Turner, J., Kim, K. I., Zurawski, S., Wang, X., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0413 · Cited by 165
Hickish, T., Andre, T., Wyrwicz, L., Saunders, M., Sarosiek, T., Kocsis, J., Nemecek, R., Rogowski, W., Lesniewski-Kmak, K., Petruzelka, L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30006-2 · Cited by 164
Yi, M., Niu, M., Zhang, J., Li, S., Zhu, S., Yan, Y., Li, N., Zhou, P., Chu, Q., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01155-6 · Cited by 163
Self-citationLow-Dose IFNγ Induces Tumor Cell Stemness in Tumor Microenvironment of Non–Small Cell Lung Cancer
Song, M., Ping, Y., Zhang, K., Yang, L., Li, F., Zhang, C., Cheng, S., Yue, D., Maimela, N. R., Qu, J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0596 · Cited by 163
Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis
Lev, S. (2020) · Biochemical Society Transactions · doi:10.1042/bst20191055 · Cited by 163
Utilizing chemokines in cancer immunotherapy
Märkl, F., Huynh, D., Endres, S., & Kobold, S. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.04.001 · Cited by 163
Li, X., Commane, M., Jiang, Z., & Stark, G. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.071054198 · Cited by 162
Brooks, D. G., Walsh, K. B., Elsaesser, H., & Oldstone, M. B. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914500107 · Cited by 161
Doi, T., Muro, K., Ishii, H., Kato, T., Tsushima, T., Takenoyama, M., Oizumi, S., Gemmoto, K., Suna, H., Enokitani, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1090 · Cited by 161
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma
Algazi, A. P., Twitty, C., Tsai, K. K., Le, M. H., Pierce, R. H., Browning, E., Hermiz, R., Canton, D. A., Bannavong, D., Oglesby, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2217 · Cited by 161
Chemokines expressed by engineered bacteria recruit and orchestrate antitumor immunity
Savage, T. M., Vincent, R. L., Rae, S. S., Huang, L. H., Ahn, A., Pu, K., Li, F., de los Santos-Alexis, K., Coker, C., Danino, T., et al. (2023) · Science Advances · doi:10.1126/sciadv.adc9436 · Cited by 161
Pandey, P., Khan, F., Upadhyay, T. K., Seungjoon, M., Park, M. N., & Kim, B. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114491 · Cited by 161
Zhang, S., Kohli, K., Black, G., Lu, Y., Spadinger, S. M., He, Q., Pillarisetty, V. G., Cranmer, L. D., Tine, B. A. V., Yee, C., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0940 · Cited by 160
Targeting STING to promote antitumor immunity
Chin, E. N., Sulpizio, A., & Lairson, L. L. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2022.06.010 · Cited by 160
Holíček, P., Guilbaud, E., Klapp, V., Truxová, I., Špíšek, R., Galluzzi, L., & Fucikova, J. P. (2023) · Immunological Reviews · doi:10.1111/imr.13272 · Cited by 159
Mechanisms of Proinflammatory Cytokine-Induced Biphasic NF-κB Activation
Schmidt, C., Peng, B., Li, Z., Sclabas, G. M., Fujioka, S., Niu, J., Schmidt‐Supprian, M., Evans, D. B., Abbruzzese, J. L., & Chiao, P. J. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00390-3 · Cited by 158
Pujade-Lauraine, E., Guastalla, J. P., Colombo, N., Devillier, P., François, E., Fumoleau, P., Monnier, A., Nooy, M., Mignot, L., Bugat, R., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.343 · Cited by 158
Yamazaki, T., Gunderson, A. J., Gilchrist, M., Whiteford, M. H., Kiely, M. X., Hayman, A. V., O’Brien, D. P., Ahmad, R., Manchio, J. V., Fox, N., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00446-6 · Cited by 158
Self-citationMcl‐1 and Bcl‐xL are co‐regulated by IL‐6 in human myeloma cells
Puthier, D., Derenne, S., Barillé‐Nion, S., Moreau, P., Harousseau, J., Bataille, R., & Amiot, M. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01705.x · Cited by 157
Lawrence, D. A. (2001) · Molecular and Cellular Biochemistry · doi:10.1023/a:1010819716023 · Cited by 157
D’Haens, G., & van Deventer, S. J. H. (2021) · Gut · doi:10.1136/gutjnl-2019-320022 · Cited by 157
Exploiting RIG-I-like receptor pathway for cancer immunotherapy
Jiang, Y., Zhang, H., Wang, J., Chen, J., Guo, Z., Liu, Y., & Hua, H. M. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01405-9 · Cited by 156
Self-citationBlocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor
Bai, X., Yi, M., Jiao, Y., Chu, Q., & Wu, K. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s224013 · Cited by 153
Self-citationWong, A. L., Soo, R. A., Tan, D. S., Lee, S. C., Lim, J. S., Marban, P. C., Kong, L. R., Lee, Y. J., Wang, L. Z., Thuya, W. L., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv026 · Cited by 153
HGF: a multifunctional growth factor controlling cell scattering
Stella, M. C. (1999) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(99)00089-8 · Cited by 151
Bessard, A., Solé-Jamault, V., Bouchaud, G., Quéméner, A., & Jacques, Y. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0275 · Cited by 151
Bilancia, D., Rosati, G., Dinota, A., Germano, D., Romano, R., & Manzione, L. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm220 · Cited by 151
Lopes, J. E., Fisher, J. L., Flick, H. L., Wang, C., Sun, L., Ernstoff, M. S., Alvarez, J. C., & Losey, H. C. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000673 · Cited by 151
Bergamaschi, C., Pandit, H., Nagy, B. A., Stellas, D., Jensen, S. M., Bear, J., Cam, M. C., Valentin, A., Fox, B. A., Felber, B. K., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000599 · Cited by 151
Roles of the CXCL8-CXCR1/2 Axis in the Tumor Microenvironment and Immunotherapy
Han, Z., Li, Y.-B., Yang, L., Cheng, H., Liu, X., & Chen, H. (2021) · Molecules · doi:10.3390/molecules27010137 · Cited by 151
Dysregulation of cellular signaling by HER2 in breast cancer
Zhou, B. P., & Hung, M.-C. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.006 · Cited by 149
Pernas, S., Martín, M., Kaufman, P. A., Gil-Martín, M., Pardo, P. G., López‐Tarruella, S., Manso, L., Ciruelos, E. M., Fidalgo, J. A. P., Hernándo, C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30147-5 · Cited by 148
Zeng, H., Hou, Y., Zhou, X., Lang, L., Luo, H., Sun, Y., Wan, X., Yuan, T., Wang, R., Liu, Y., et al. (2022) · Theranostics · doi:10.7150/thno.74753 · Cited by 146
FGFR-TKI resistance in cancer: current status and perspectives
Yue, S., Li, Y., Chen, X., Wang, J., Li, M., Chen, Y., & Wu, D. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01040-2 · Cited by 145
Badran, Y. R., Cohen, J. V., Brastianos, P. K., Parikh, A. R., Hong, T. S., & Dougan, M. L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0711-0 · Cited by 144
Tichet, M., Wullschleger, S., Chryplewicz, A., Fournier, N., Marcone, R., Kauzlaric, A., Homicskó, K., Deak, L. C., Umaña, P., Klein, C., et al. (2023) · Immunity · doi:10.1016/j.immuni.2022.12.006 · Cited by 144
The chemokine monocyte chemoattractant protein-1/CCL2 is a promoter of breast cancer metastasis
Yoshimura, T., Li, C., Wang, Y., & Matsukawa, A. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01013-0 · Cited by 143
IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19
Kishimoto, T., & Kang, S. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101220-023458 · Cited by 140
Zou, J., Presky, D. H., Wu, C. Y., & Gubler, U. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.9.6073 · Cited by 139
IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer
Felices, M., Chu, S., Kodal, B., Bendzick, L. E., Ryan, C. J., Lenvik, A. J., Boylan, K. L. M., Wong, H. C., Skubitz, A. P. N., Miller, J. S., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.02.028 · Cited by 139
IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma
Weber, R., Riester, Z., Hüser, L., Sticht, C., Siebenmorgen, A., Groth, C., Hu, X., Altevogt, P., Utikal, J. S., & Umansky, V. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000949 · Cited by 139
Syed, Y. Y. (2021) · Drugs · doi:10.1007/s40265-021-01561-7 · Cited by 139
A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors
Xue, D., Moon, B., Liao, J., Guo, J., Zou, Z., Han, Y., Cao, S., Wang, Y., Fu, Y., & Peng, H. (2022) · Science Immunology · doi:10.1126/sciimmunol.abi6899 · Cited by 139
CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion
Jiao, X., Velasco-Velázquez, M. A., Wang, M., Li, Z., Rui, H., Peck, A. R., Korkola, J. E., Chen, X., Xu, S., DuHadaway, J. B., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-0915 · Cited by 138
Cited by
The Role of Inflammation in Cancer: Mechanisms of Tumor Initiation, Progression, and Metastasis
Nishida, A., & Andoh, A. (2025) · Cells · doi:10.3390/cells14070488 · Cited by 270
Metadata
- Authors
- Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-07-22
- Volume
- 9
- Issue
- 1
- Pages
- 176-176
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4400867712
- Cited by
- 455
- References
- 628
- FWCI
- 69.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.